148 related articles for article (PubMed ID: 21917520)
1. Anthracyclines, HER2, and TOP2A: the verdict.
Bonnefoi HR
Lancet Oncol; 2011 Nov; 12(12):1084-5. PubMed ID: 21917520
[No Abstract] [Full Text] [Related]
2. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
3. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
Pritchard KI
J Clin Oncol; 2009 Aug; 27(24):3875-6. PubMed ID: 19620479
[No Abstract] [Full Text] [Related]
4. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
5. Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
Munro AF; Bartels A; Balslev E; Twelves CJ; Cameron DA; Brünner N; Bartlett JM
Breast Cancer Res; 2013 Apr; 15(2):R31. PubMed ID: 23570501
[TBL] [Abstract][Full Text] [Related]
6. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
8. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ
J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
Buzdar AU
J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
[No Abstract] [Full Text] [Related]
10. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J; Kristel P; van Tinteren H; Bontenbal M; van Hoesel QG; Smit WM; Nooij MA; Voest EE; van der Wall E; Hupperets P; de Vries EG; Rodenhuis S; van de Vijver MJ
Br J Cancer; 2006 Nov; 95(10):1334-41. PubMed ID: 17088909
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
Slamon DJ; Press MF
J Natl Cancer Inst; 2009 May; 101(9):615-8. PubMed ID: 19401550
[No Abstract] [Full Text] [Related]
12. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
14. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
Simon R
J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
[No Abstract] [Full Text] [Related]
15. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
[TBL] [Abstract][Full Text] [Related]
16. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
19. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
20. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]